Cytokinetics (NASDAQ:CYTK) Posts Earnings Results, Misses Estimates By $0.02 EPS

Cytokinetics (NASDAQ:CYTK) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02), Zacks reports. The business had revenue of $17.76 million during the quarter, compared to analysts’ expectations of $8.02 million. During the same period in the prior year, the firm posted ($1.26) earnings per share. The business’s quarterly revenue was up 4.9% compared to the same quarter last year.

Here are the key takeaways from Cytokinetics’ conference call:

• MYQORZO received FDA approval for symptomatic obstructive HCM in the U.S., approvals in China, and European Commission approval after a CHMP positive opinion, marking Cytokinetics’ transition to a global commercial-stage company.
• U.S. launch activity is underway with the REMS portal and patient support program live, first prescriptions dispensed, over 700 REMS‑certified HCPs and strong early engagement; the company targets >50% CMI new‑patient preference share by end‑2026.
• Key clinical milestones ahead: top‑line results for ACACIA‑HCM (non‑obstructive HCM) expected in Q2 2026 and a submitted sNDA for MAPLE‑HCM with FDA review targeted for Q4 2026 — both could expand the label but outcomes remain uncertain.
• Financials show ~$1.22B in year‑end cash but widening 2025 net losses and a 2026 GAAP R&D+SG&A expense guide of $830–$870M with no product‑sales guidance, implying significant near‑term spend and execution risk.

Cytokinetics Trading Down 1.8%

CYTK stock traded down $1.11 during midday trading on Thursday, reaching $61.78. The company had a trading volume of 790,139 shares, compared to its average volume of 1,804,781. The company has a 50 day moving average of $64.21 and a two-hundred day moving average of $58.35. The company has a market capitalization of $7.55 billion, a P/E ratio of -9.53 and a beta of 0.54. Cytokinetics has a 1 year low of $29.31 and a 1 year high of $70.98.

Analyst Upgrades and Downgrades

CYTK has been the topic of a number of research reports. Barclays started coverage on shares of Cytokinetics in a report on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 target price on the stock. Wall Street Zen lowered Cytokinetics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. B. Riley Financial boosted their target price on Cytokinetics from $90.00 to $108.00 and gave the stock a “buy” rating in a research report on Wednesday, January 21st. Leerink Partners set a $83.00 price objective on Cytokinetics in a report on Monday, December 22nd. Finally, The Goldman Sachs Group set a $95.00 target price on shares of Cytokinetics and gave the stock a “buy” rating in a report on Thursday, December 18th. Sixteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $88.78.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: MYQORZO approved in the U.S., China and Europe with U.S. launch underway and first prescriptions already dispensed; company says supplemental NDA for MAPLE‑HCM submitted and ACACIA‑HCM topline expected in Q2 — strong commercial and clinical catalysts. Company Press Release
• Positive Sentiment: Revenue beat estimates materially for Q4 ($17.7M vs. ~$8.0M consensus) and the company reported roughly $1.2B in cash, which supports launch execution and near-term R&D. Financial Results
• Positive Sentiment: Analysts raised targets and reiterated buys: Citizens JMP and Needham lifted targets (coverage noted by Benzinga) and HC Wainwright maintains a Buy with a $136 target — these raise upside expectations among investors. Analyst Notes HC Wainwright Coverage
• Neutral Sentiment: Earnings call transcripts and coverage are available for detail on launch plans and cost outlook — useful for active investors but not market-moving by themselves. Earnings Transcript
• Neutral Sentiment: Reported short-interest data is effectively zero/ambiguous for February, so short-covering dynamics are unlikely to be a near-term driver.
• Negative Sentiment: Q4 EPS missed slightly (‑$1.50 vs. consensus ‑$1.48) and commentary flagged higher expenses tied to launch and growth initiatives — a reminder that profitability remains distant and near-term losses may continue to pressure the stock. Earnings & Analysis

Insiders Place Their Bets

In other Cytokinetics news, EVP Andrew Callos sold 52,486 shares of the company’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $65.95, for a total value of $3,461,451.70. Following the transaction, the executive vice president directly owned 50,660 shares of the company’s stock, valued at $3,341,027. This represents a 50.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Fady Ibraham Malik sold 2,200 shares of Cytokinetics stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $61.24, for a total value of $134,728.00. Following the sale, the executive vice president owned 138,552 shares of the company’s stock, valued at approximately $8,484,924.48. This represents a 1.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 151,385 shares of company stock valued at $9,817,158 in the last three months. Company insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Cytokinetics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CYTK. Millennium Management LLC grew its position in Cytokinetics by 361.9% in the first quarter. Millennium Management LLC now owns 287,901 shares of the biopharmaceutical company’s stock worth $11,571,000 after acquiring an additional 225,576 shares in the last quarter. Cetera Investment Advisers raised its holdings in shares of Cytokinetics by 12.4% during the 2nd quarter. Cetera Investment Advisers now owns 6,635 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 731 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Cytokinetics by 723.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 673 shares during the last quarter. Gabelli Funds LLC boosted its holdings in Cytokinetics by 29.4% in the second quarter. Gabelli Funds LLC now owns 8,410 shares of the biopharmaceutical company’s stock worth $278,000 after purchasing an additional 1,910 shares in the last quarter. Finally, California Public Employees Retirement System increased its position in Cytokinetics by 10.8% during the second quarter. California Public Employees Retirement System now owns 142,602 shares of the biopharmaceutical company’s stock worth $4,712,000 after buying an additional 13,911 shares during the last quarter.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.